266 related articles for article (PubMed ID: 18076216)
1. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
Murthy B; Schmitt-Hoffmann A
Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
[TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
3. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Dauner DG; Nelson RE; Taketa DC
Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
[TBL] [Abstract][Full Text] [Related]
6. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Noel GJ
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
[TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
9. Ceftobiprole medocaril: a new generation beta-lactam.
Del Pozo JL; Patel R
Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
[TBL] [Abstract][Full Text] [Related]
10. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
11. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
12. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Syed YY
Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
[TBL] [Abstract][Full Text] [Related]
13. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Vidaillac C; Rybak MJ
Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
18. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
Craig WA; Andes DR
Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
